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Abstract 
Background:  Endoscopic ultrasound (EUS) provides high-resolution images of the 
pancreas.  There are two fundamental echoendoscope designs, yet no data support use 
of one type over the other.  Once lesion is detected, EUS-guided fine-needle aspiration 
(FNA) is performed, but standard (STN) processing techniques can be associated with 
limited cellularity, leading to evaluation of novel filter-clot (FC) cellblock technique.  
With improved quality of EUS-FNA samples, it may be possible to pre-operatively 
evaluate biomarker status of pancreatic lesions to better risk stratify and tailor future 
treatments to individual patients.   Aims: 1) To compare pancreatic lesion detection 
rates using radial and linear EUS and to determine incremental diagnostic yield of 
second EUS exam in tandem study.   2) To compare diagnostic yield and accuracy of STN 
and FC techniques of processing EUS-FNA samples. 3) To determine whether DPC4 gene 
status using EUS-FNA samples correlate with clinical outcomes in pancreatic cancer (PC) 
patients.   
Methods:   High-risk individuals (HRIs) in screening program underwent radial or linear 
EUS or tandem radial and linear EUS in randomized order.  Pancreatic lesion detection 
rates were compared.  EUS-FNA samples during a 13-month period were used to 
compare the sample adequacy and diagnostic accuracy of STN and FC techniques. 
Retrospective review was performed evaluating whether Dpc4 immunolabeling status in 
EUS-FNA samples of PC patients correlated with pattern of disease progression and 
clinical outcomes.   
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Results:  In HRIs, linear EUS detected more pancreatic lesions than radial EUS.  In 
tandem EUS exams, second EUS detected additional lesions, whether the initial exam 
was performed with radial or linear EUS.  However, incremental detection rate was 
significantly higher if the second exam was linear EUS.  FC technique had higher sample 
adequacy and diagnostic accuracy than STN technique.  DPC4 status was associated with 
pattern of failure, with DPC4 negative PC more likely to progress with metastasis.   
Conclusion:  Linear EUS should be the echoendoscope of choice in pancreatic imaging.  
FC technique was associated with improved quality of EUS-FNA samples.  DPC4 status 
correlated with disease progression phenotypes in PC patients.  Pre-operative 
biomarker studies using EUS-FNA samples have the potential to advance the concept of 
personalized medicine in the field of pancreatic oncology.        
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Pancreatic Cancer: Why Consider Screening? 
 
Pancreatic cancer remains one of the most deadly diseases, despite significant advances 
in medicine over the past decade.  Pancreatic adenocarcinoma is the fourth leading 
cause of cancer deaths in the United States for both males and females with an 
estimated 44,030 new cases and 37,660 deaths in 2011.1  In contrast to the other 
leading causes of cancer death (lung, colorectal, breast, and prostate) which has shown 
a decline since 2003, the death rate from pancreatic adenocarcinoma has increased 
during the same time period.1  Unfortunately, majority of the symptomatic patients are 
incurable.  The prognosis for patients with pancreatic adenocarcinoma remains poor, 
with 5-year relative survival rate of only 6% for all stages combined likely due to the late 
stage of disease at the time of diagnosis.  Hence, there has been strong interest in 
detecting precursor lesions or small asymptomatic cancers which are potentially 
curable.   Widespread screening program does not seem feasible or cost-effective given 
the relative low incidence of the disease, accounting for only 3% of all new cancer cases 
in the United States, and the lack of accurate, inexpensive, and non-invasive diagnostic 
tests for early lesions.  However, screening may be desirable in selected population with 
increased risk for developing pancreatic adenocarcinoma. 
 
Genetic Predisposition to Pancreatic Cancer 
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Although the great majority of pancreatic adenocarcinoma cases are thought to be 
sporadic in nature, it has been estimated that up to 10% of cases can be attributed to 
genetic factors. 2-4  In fact, familial clustering of pancreatic cancer was noted as early as 
1967 when Lynch reported on an adenocarcinoma-prone family.5  Familial pancreatic 
cancer (FPC) is characterized by two or more first-degree relatives with pancreatic 
adenocarcinoma in the absence of a known cancer syndromes or other diseases with 
known genetic defect.  Individuals from a family with a pair of affected first-degree 
relatives have a higher risk (6.4-fold to 32-fold) of developing pancreatic cancer.6-9  Thus 
far, the key causative gene or genes leading to the inherited predisposition in familial 
pancreatic cancer have not yet been fully elucidated.  Complex segregation analysis 
suggests that this predisposition may be due to a novel rare major gene with an 
autosomal dominant inheritance with reduced penetrance.10-13   
 
Initial linkage analysis suggested that the palladin gene may be one of the FPC gene 
where a base pair change appeared to track with the development of pancreatic cancer 
in the specific kindred.14  However, the initial excitement has been tempered by the 
failure of population-based studies in Canada and Europe to demonstrate that 
mutations in the PALLD gene are more common in those with FPC compared to 
controls.15-18  Furthermore, a study evaluating the pattern of palladin protein expression 
in 177 cases of pancreatic adenocarcinoma determined that while the palladin protein is 
over-expressed in the stroma, it is not over-expressed in the neoplastic cells in 
pancreatic cancer.19   
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To date, germline BRCA2 mutation appears to be the most common genetic abnormality 
in patients who develop pancreatic adenocarcinoma from familial pancreatic cancer 
kindreds, but still have only been reported in 6-19% of all FPC kindreds.20-22  Mutations 
in the BRCA2 gene can be present even when in the absence of breast or ovarian cancer, 
and in apparently sporadic pancreatic cancer.  Recent studies have identified a another 
associated inheritable gene mutation called PALB2 (partner and localizer for breast 
cancer 2 gene) as a pancreatic adenocarcinoma susceptibility gene, which may also be 
causative for 3-4% of FPC.7, 9  The PALB2 protein directly binds BRCA1 and acts as a 
bridge between BRCA1 and BRCA2 to form a complex involved in double-strand break 
repair.23 The PALB2 gene is present in 1-2% of famililal breast cancer.  Subsequent 
testing of patients with a personal history of breast and pancreatic cancer24 and non-
BRCA1/2 breast cancer women with a personal or family history of pancreatic cancer25 
have shown the PALB2 mutation to be very uncommon mutation. The clinical utility of 
routine testing of FPC patients for PALB2 has not been proven. 
 
Inherited Cancer Syndromes 
 
Hereditary Pancreatitis 
Hereditary pancreatitis is a rare inherited disorder characterized by recurrent 
attacks of acute pancreatitis in childhood or early adolescence, followed by 
development of chronic pancreatitis in late adolescence or early adulthood.26  It is 
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transmitted as an autosomal dominant disorder with incomplete penetrance.27  Most 
are due to germline gain-of-function mutations in a cationic trypsinogen gene (PRSS1) 
on chromosome 7q35.28-30 Mutations in PRSS1 result in premature trypsin activation and 
ineffective autodegradation of active trypsin mutants, leading to autodigestion and 
acute pancreatitis.31  Hereditary pancreatitis is associated with one of the highest 
estimated lifetime risks for developing pancreatic cancer among the inherited 
pancreatic cancer syndrome, with lifetime risk approaching 40%. 32, 33  Particularly in 
those individuals with a paternal inheritance pattern, the cumulative risk for developing 
pancreatic cancer is approximately 75%.32  Tobacco smoking increases the risk even 
further in this population by approximately 2-fold and decreases the age of onset of 
pancreatic cancer by approximately 20 years.27, 34 
 
Peutz-Jeghers Syndrome (PJS) 
Peutz-Jeghers syndrome (PJS) is an autosomal dominantly inherited polyposis 
syndrome with high penetrance.  The reported frequency of PJS is 1 in 8300 to 280,000 
individuals.35  It is characterized by hamartomatous polyps of the gastrointestinal 
(GI)tract and mucocutaneous pigmentation.  It is caused by inherited germline mutation 
of the STK11/LKB1 tumor suppressor gene.36  Patients with PJS have a significantly 
increased lifetime risk for multiple GI cancers, including esophagus (0.5%), stomach 
(29%), small intestine (13%), and colon (39%).37  They are also at increased risk for non-
GI cancers, including breast (54%), lung (15%), ovaries (21%), cervix (10%), uterus (9%), 
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and testicles (9%).  The cumulative lifetime risk for developing pancreatic cancer is 36%, 
with relative risk of 132.37  
 
Familial Atypical Multiple Mole Melanoma (FAMMM)   
Familial atypical multiple mole melanoma (FAMMM) is an autosomally dominant 
disease with variable penetrance.  It is characterized by familial occurrence of multiple 
benign melanocytic nevi, dysplastic nevi, and melanoma.38  It is associated with germline 
mutations in the p16/CDKN2A gene.39, 40  In addition to pancreatic cancer, FAMMM is 
associated with an increased risk of sarcomas, endometrial, breast, and lung cancers.41, 
42  There is approximately 13-fold to 22-fold increased risk of pancreatic cancer in 
FAMMM compared to the general population.42, 43   
 
Lynch Syndrome 
Patients with hereditary non-polyposis colorectal cancer syndrome (HNPCC or 
Lynch Syndrome) have mutations in the mismatch repair genes (MLH1, MSH2, MSH6, 
and PMS2).  It is characterized by early-onset colorectal cancer.  They are also prone to 
develop other types of cancers, including endometrial, gastric, renal, ureteral, and small 
intestinal cancers.44  Lifetime risk of pancreatic cancer in patients with Lynch syndrome 
is 3.7% up to the age of 70, which is an 8.6-fold increased risk compared to the general 
population.45   
 
Familial Breast-Ovarian Cancer (FBOC) 
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Familial breast-ovarian cancer syndrome is an autosomal dominantly inherited 
syndrome associated with germline mutations in BRCA1 (breast related cancer 1) and 
BRCA2 (breast related cancer 2) tumor suppressor genes involved in repair of DNA 
damage.  Carriers of the gene mutations are at a high risk for developing early-onset 
breast and/or ovarian cancers, as well as cancers of the gallbladder and bile duct (RR 
4.97), prostate (RR 4.65), stomach (RR 2.59) and malignant melanoma (RR 2.58).46  
BRCA1 mutation is associated with a 2.3-fold to 3.6-fold increased risk 47, 48 and BRCA2 
mutation is associated with a 3-fold to 10-fold increased risk for pancreatic cancer.46, 49, 
50  Furthermore, in patients with sporadic pancreatic cancer, 7.3% had germline BRCA2 
mutation.51  Approximately 1% of the general Ashkenazi Jewish population carry each of 
the BRCA1 and BRCA2 founder mutations.52, 53  Studies have shown that in patients of 
Ashekenazi Jewish descent with pancreatic adenocarcinoma, 5.5-10% of them will have 
BRCA2 mutation.52-55   
 
Targets for Screening and Surveillance 
 
The ideal screening strategy for pancreatic cancer would target high grade benign, 
noninvasive precursor neoplastic lesions (pancreatic intraepithelial neoplasias called 
PanINs or intraductal papillary mucinous neoplasms called IPMNs) before malignant 
transformation or disease at an early stage which would allow for curative surgical 
resection.56  Although IPMNs can be detected as cystic lesions and/or a dilated main 
pancreatic duct, PanINs are small branch ducts < 5 mm in size, often microscopic, and 
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not reliably visualized by clinical imaging tests.  Hence, the optimal strategy for 
detection of early pancreatic neoplasia may need to involve biomarker tests alone or in 
combination with imaging. 
 
Available and Anticipated Tumor Markers 
 
Currently, there is no biomarker with adequate sensitivity and specificity which can be 
used for routine clinical screening.57   Given the typical late stage of disease at the time 
of diagnosis, there has been much effort invested in identifying accurate tumor markers 
to aid in early diagnosis of pancreatic cancer.   
 
The most widely used serum marker in patients with pancreatic cancer is sialylated 
Lewis blood group antigen on MUC-1 (Mucin 1, cell surface associated), carbohydrate 
antigen 19-9 (CA 19-9).  It is a cell surface glycoprotein expressed by pancreatic cancer 
cells, but is also found in normal pancreatic and biliary duct cells, and gastric colonic, 
endometrial, and salivary epithelia.58  Consequently, CA 19-9 is not routinely used for 
diagnosis because of the unacceptably high rate of false-positive results, with specificity 
ranging from 33% to 100%.59-61  
 
CA 19-9 is also associated with imperfect sensitivity, ranging from 41% to 86%.59, 61  
Approximately 4-15% of the general population do not express Lewis antigen and 
therefore do not have detectable CA 19-9 levels.61-65  In patients with resectable 
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pancreatic cancer, CA 19-9 level is elevated in only 65% of these patients.61  The marker 
is also inadequate to reliably differentiate between pancreatic cancer and chronic 
pancreatitis, as up to 40% of patient with chronic pancreatitis can exhibit elevated levels 
of CA 19-9.61, 66  Given its performance characteristics as a biomarker in the general 
population, serum CA 19-9 is used primarily for monitoring of responses to therapy in 
patients already diagnosed with cancer rather than for early diagnosis.61, 67-69  One 
recent feasibility study in individuals with one or more first-degree relative with 
pancreatic cancer used serum CA19-9 as a screening test followed by EUS in those with 
elevated levels and detected one asymptomatic pancreatic ductal adenocarcinom (PDA) 
in 546 individuals70.  
 
Carcinoembryonic antigen (CEA) was the first biomarker used for diagnostics.  Several 
studies have demonstrated high levels of CEA in the pancreatic juice of patients with 
pancreatic cancer compared to those with benign pancreatic disease.71-74  When the CEA 
cut-off level was set at 50ng/mL, the positive predictive value (PPV), negative predictive 
value (NPV), and accuracy for diagnosing pancreatic cancer were 77%, 95%, and 85%, 
respectively.71, 75  The main limitation of CEA is the low sensitivity, ranging from 25%-
56% with relatively high specificity, ranging from 82%-100% in distinguishing pancreatic 
cancer from benign pancreatic diseases.59, 76-81 
 
Much of the initial efforts in identifying novel markers of pancreatic cancer have focused 
on carbohydrate antigens of MUC-1 in hopes of improving the performance of CA 19-9.  
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PAM4 is an anti-MUC1 monoclonal antibody which appears to detect MUC-1 expressed 
by pancreatic cancer MUC-1 protein more specifically than MUC-1 proteins from other 
cancers (e.g., breast, ovarian, etc).82 Furthermore, in comparison with CA 19-9, PAM4 
demonstrated higher sensitivity and specificity in discriminating patients with pancreatic 
cancer from those with chronic pancreatitis (p<0.003).82  As expected, patients with 
advanced disease had significantly higher levels that those with early disease.  
Diagnostic sensitivity of PAM4 for stage 3/stage 4 disease was 91%, for stage 2 was 86%, 
and for stage 1 was 62% (stage 1A 54% and stage 1B 75%).83  Further supporting the 
potential role of PAM4 in detecting early-stage pancreatic cancer, PAM4 expression was 
detected in precursor lesions of pancreatic adenocarcinoma, positive in 89% of 
pancreatic intraepithelial neoplasias (PanIN) and 86% of intraductal papillary mucinous 
neoplasms (IMPN) examined, including 94% of the earliest neoplastic lesions, PanIN-1A 
and 1B.84  
 
Recent studies have identified other potential biomarkers for pancreatic cancer, 
including CA494,85 CEACAM1,86  PTHrP,87 TuM2-PK,88 CAM 17.1,78 and serum beta 
HCG.89 Although their performance characteristics in initial studies are promising, larger 
studies are needed to confirm their clinical applicability and are currently used only in 
research setting.   
 
Pancreatic juice sample provides a rich medium for genetic and epigenetic marker 
analysis.  Pancreatic juice samples can be obtained at the time of EUS (secretin-
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stimulated) or ERCP (duodenal aspirate90 or pure pancreatic juice).57  Markers which 
have been studied in pancreatic juice include K-ras mutations, p53 mutations, DNA 
methylation aberrations, and mitochondrial DNA mutations.61  Mutant K-ras is a marker 
of interest because mutations are present in 90% of pancreatic adenocarcinoma and has 
been measured in pancreatic juice samples.  However, its sensitivity and specificity for 
pancreatic cancer are poor (sensitivity 38-62%; specificity 88-90%), likely due to the fact 
mutant K-ras can also be found in chronic pancreatitis and in PanINs without pancreatic 
cancer.57, 90-96 p53 mutations are found in approximately 70% of invasive pancreatic 
adenocarcinoma91 and has been detected in 40-50% of pancreatic juice samples and 
brush cytology specimens with patients with pancreatic cancer.97  DNA promoter 
methylation alterations has been investigated in multiple candidate genes, including 
p16,98, 99 RELN,100 DAB1,100 ppENK,101, 102 Cyclin D2,103 SOCS1,104 SPARC,105 TSLC1,106 and 
others.61, 102, 107  DNA promoter hypermethylation status was quantified in a panel of 
candidate genes (Cyclin D2, FOXE1, NPTX2, ppENK, p16, and TFP12) in pure pancreatic 
juice obtained from patients with pancreatic ductal adenocarcinoma, intraductal 
papillary mucinous neoplasms, chronic pancreatitis and controls with no known 
pancreatic disease, as well as a cohort of high-risk individuals from familial pancreatic 
cancer kindreds.  This method demonstrated high sensitivity (82%) and specificity 
(100%) in identifying patients with pancreatic cancer.108  Mitochondrial DNA mutations 
are commonly found in multiple cancers.61, 109-113  Using chip technologies, initial studies 
appear to suggest that mitochondrial mutations can be reliably detected in pancreatic 
juice samples from patients with pancreatic cancer.61, 111   
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Approaches to Screening 
 
Currently, there is no sufficiently sensitive, specific, and reliable screening test for the 
early detection of pancreatic cancer.  The great majority of pancreatic cancers are 
considered sporadic, accounting for at least 90% of all patients.  The detection rate is 
low in average risk individuals because pancreatic cancer is a rare disease, despite its 
deadly nature.  In screening studies performed in Japan, 5 cancers were found in 2511 
individuals.  Given the overall low incidence of disease and the current lack of accurate, 
inexpensive, and non-invasive screening tests, the consensus is that widespread 
population-based screening for pancreatic cancer in the general population or those 
with only one affected first-degree relative is neither feasible nor indicated in most 
countries.56  Selective screening of patients with increased risk for pancreatic ductal 
adenocarcinoma has been performed in high risk patients from familial pancreatic 
cancer kindreds and patients with inherited cancer syndromes.56, 114, 115   
 
The various approaches to screening and results of screening tests for asymptomatic 
pancreatic neoplasms are summarized in Table 1.  One approach is population-based 
screening, such as that performed in Japan with abdominal ultrasound (with199 or 
without116 MRI).  A second approach is the use of a serum biomarker, such as serum 
CA19-9 followed by a pancreatic imaging test70.  A third approach uses only abdominal 
imaging tests, such as computed tomography, magnetic resonance imaging, endoscopic 
12 
     
ultrasonography (EUS), or endoscopic retrograde cholangiopancreatography (ERCP),  in 
combination or in sequence (i.e. EUS following MRI/MRCP or CT if abnormal).   
 
Multi-detector computed tomography (MDCT) is currently the abdominal imaging test 
of choice for pancreatic disease, particularly for diagnosis of solid tumors and staging of 
pancreatic cancer.117, 118  Despite the high accuracy for detecting and staging of 
pancreatic malignancies, the sensitivity of MDCT may be suboptimal and may still miss 
lesion when used for screening for early pancreatic neoplasia.114, 115, 118  Sensitivity of 
thin section triple phase helical CT to detect lesions smaller than 2cm was only 70-
80%.56, 119  Recent studies have shown that MDCT has a negative predictive value of 87% 
for tumor respectability120 and an accuracy rate of 85-95%.75, 121, 122  Furthermore, there 
is also a concern for radiation exposure if CT is used as a part of a long-term 
screening/surveillance program, particularly in individuals with impaired DNA mismatch 
repair gene function due to BRCA1/2  or PALB2 gene mutation. Hence, CT scan is not the 
ideal screening or surveillance imaging test for high risk individuals.  Furthermore, MDCP 
with a pancreatic protocol may not be as sensitive as EUS in at-risk individuals from FPC 
kindreds114, 115, 123, 124. 
 
Magnetic resonance imaging (MRI) may be an interesting choice for non-invasive 
imaging test for screening high-risk patient because it is able to image the entire 
abdomen and pelvis (unlike EUS) while avoiding the radiation risk (unlike CT).  Magnetic 
resonance cholangiopancreatography (MRCP) is able to non-invasively image pancreatic 
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ductal anatomy (unlike ERCP) and small cystic lesions, such as IPMNs.  Preliminary data 
from high-risk patients who underwent surgical resection suggests that MRI/MRCP may 
be superior to CT, particularly for detection of IPMNs (71% versus 14%, p<0.0001).56, 124  
A prospective MRI-based screening study of 79 patients aged 39-72 with a p16 Leiden 
mutation (associated with FAMMM syndrome) has shown that early-stage pancreatic 
cancers can be detected at baseline and during follow-up125.  After a median follow-up 
period of 4 years (range, 0-10 years), pancreatic cancer was diagnosed in 7 patients 
(9%). The mean age at diagnosis was 59 years (range, 49-72 years). Three of the 
asymptomatic pancreatic cancers were present at the first examination, and 4 were 
detected after a negative result in the initial examination. All 7 patients with cancer had 
a resectable lesion but 5 underwent surgery (3 had an R0 resection, and 2 had lymph 
node metastases). Furthermore, possible precursor lesions (ie, duct ectasias or branch-
duct IPMNs, based on MRCP) were found in 9 individuals (11%). 
 
Endoscopic ultrasound (EUS) has been used to screen high-risk individuals in several 
screening programs.60, 114, 115, 126, 127  It can provide high-resolution images of the 
pancreas without the risk of radiation exposure and can image mural nodules (focal 
thickening of the wall in branch duct IMPNs), which are associated with increased risk of 
malignancy. 57, 118, 128  The disadvantage of EUS is that it is operator-dependent and is an 
endoscopic procedure with inherent risk of procedure and sedation, which may limit its 
role in widespread screening and surveillance program.  Preliminary analysis of high-risk 
individuals enrolled in a screening program who underwent surgical resection suggest 
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that EUS can detect almost twice as many neoplastic lesions as CT or MRI/MRCP56, 124.  
Published studies using EUS-based screening for high risk individuals have reported 
detection of asymtptomatic precancerous branch duct IPMNs, large PanIns, incidental 
pancreatic endocrine tumors, and ductal adenocarcinomas.  One Dutch study of 
BRCA1/2 and p16 germline mutation carriers, patients with Peutz-Jeghers syndrome, 
and relatives of patients reported the high one-time yield of EUS-based screening. The 
authors found a 6.8% prevalence (n=3 of 44 individuals screened) of asymptomatic 
pancreatic ductal adenocarcinomas (12, 20, and 50 mm in size)126.  All cancers were 
completely resected but 2 already had lymph node metastases at presentation. 
Furthermore, the diagnostic yield of EUS-based screening for prevalent precursor 
branch duct IPMNs was 16%126. 
 
The clinical utility of ancillary studies such as fine needle aspiration (FNA) and 
endoscopic retrograde cholangiopancreatography (ERCP) is not clear.  EUS-FNA has 
been used to investigate pancreatic cystic lesions and can provide a cytologic diagnosis 
of IPMN in 71% of the cases.129  The need for routine FNA of pancreatic cysts in a high 
risk population has not been proven, given the typically small size of branch duct IPMNs 
(comprising the vast majority of cystic lesions) detected not requiring surgical 
treatment. EUS-FNA can also lead to false positive results if cytological aspirates show 
severe dysplasia or findings suspicious for ductal adenocarcinoma leading to potentially 
unnecessary surgery114.  ERCP has been used routinely in high risk patients from FPC 
relatives with abnormal EUS, but this resulted in a post-ERCP pancreatitis rate of 7%114 
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in one study.  Furthermore, ERCP did not reliably demonstrate ductal communication of 
branch duct IPMNs or lead to additional clinically-relevant imaging findings. Hence, most 
formal screening programs around the world do not recommend routine ERCP for 
asymptomatic individuals. 
 
In summary, there is accumulating data that clinically available abdominal imaging tests 
such as EUS and MRI/MRCP can detect asymptomatic precursor benign (IPMN, PanIN) 
and invasive malignant pancreatic neoplasms such as ductal adenoarcinoma in 
individuals with an inherited predisposition.  These asymptomatic FPCs detected have 
been more likely to be resectable, compared to symptomatic tumors.  The most 
challenging part of screening high risk individuals is selection of individuals with high 
grade precursor neoplasms for preventive treatment (i.e. surgical resection prior to 
development of invasive cancer). Ongoing and future research should focus on 
formulating and validating a predictive model for FPC risk and neoplastic progression 
using patient characteristics, imaging, and biomarkers.  The comparative cost and 
effectiveness of various approaches for screening and surveillance of high risk 
individuals also deserves study.  For now, screening is best performed in high risk 
individuals within research protocols in academic centers with multidisciplinary teams 
with expertise in genetics, gastroenterology, radiology, surgery, and pathology.  
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Table 1:  Approaches to Pancreatic Screening 
 Sequential 









 Transabdominal US 
followed by non-
contrast MRI/MRCP, 
prospective study in 




in 130,951 patients 




followed by EUS if > 
37 U/ml detected 
in 546 individuals 
with >= 1 FDR with 
PC found 
pancreatic 
neoplasms in 5/546 
(1 early cancer) 
MRI/MRCP or CT 
followed by EUS in 
FPC relatives found 
IPMN and PDA in 
8.3%131 
MRI/MRCP only in 
79 p16 mutation 
carriers detected 5 
cancers125 
  EUS followed by 
ERCP (when 
EUS + MRI/MRCP in 
FPC relatives 
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and/or PDA132, 123  
   EUS + MDCT in FPD 
relatives detected 
IPMNs, PNET, and 
PDA114, 115 
   EUS only in FPC 
relatives and 
mutation carriers 






     
Chapter 2:  Radial versus Linear and Second Look Endoscopic Ultrasound (EUS) 




     
Introduction: 
 
Endoscopic ultrasonography (EUS) is increasingly used as a diagnostic test for imaging 
pancreatobiliary abnormalities.  In particular, when evaluating the pancreas for early 
neoplastic changes or lesions, magnetic resonance imaging (MRI) and EUS appear to be 
better imaging modalities than computed tomography (CT) in detecting small and early 
lesions, especially in asymptomatic high-risk individuals (HRIs) undergoing screening 
program.1-8      
 
There are two fundamental types of echoendoscopes in clinical practice today, radial 
and linear array echoendoscope.9, 10  Radial array echoendoscopes produce ultrasound 
images perpendicular to the axis of the endoscope tip with 360 degrees scanning range.  
The circumferential images produced are oriented similar to that of the cross-sectional 
CT and are often easier to interpret for a novice endosonographer.  Radial EUS is used 
most often in diagnostic examination as the orientation of the transducers limit 
ultrasound-guided biopsy and therapeutic interventions.  Linear array echoendoscopes 
produce ultrasound images parallel to the direction of insertion of the endoscope, with 
scanning range between 100 and 180 degrees. Linear array echoendoscopes offer a 
distinct advantage over the radial array echoendoscopes since fine needle aspiration 
(FNA) and therapeutic interventions are able to be performed through the instrument 
channel under real-time guidance.   
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Linear EUS is currently favored by many endosonographers for pancreatic imaging, 
regardless of whether or not FNA is required.11, 12  However, no studies support the 
systematic use of linear over radial EUS for detection of non-malignant pancreatic 
lesions.  Published data directly comparing radial and linear EUS have evaluated its role 
in diagnosing and staging pancreatic malignancies 13-17 and in diagnosing chronic 
pancreatitis with variable outcomes.18, 19 In the published paper and abstract addressing 
the performance characteristics of EUS in non-malignant pancreatic imaging, radial and 
linear array EUS were found to be comparable in the diagnosis of chronic pancreatitis by 
EUS criteria.18,19 
 
In the field of screening colonoscopy and adenoma detection, pooled results from 
tandem colonoscopy studies have shown a 22% miss rate for colon adenoma 
detection.20-29   However, in the field of pancreatic diagnostic imaging, the miss rate for 
EUS detection of pancreatic lesions is unknown.  
 
The primary aims of the study were to compare the pancreatic lesion detection rates 
using radial array and linear array EUS in a well-defined, asymptomatic high risk 
population undergoing pancreatic screening and to determine the incremental 





     
Study design:   
This was a cohort study with embedded randomized tandem study as part of the multi-
center American Cancer of the Pancreas Screening (CAPS 3) Consortium study, involving 
5 academic centers.  Endoscopic ultrasound (EUS) was performed as a part of the 
baseline screening evaluation by expert endosonographers at each participating 
institution on an outpatient basis.  The institutional review boards of all 5 participating 
institutions approved the research protocol.   
 
Study population:   
Consecutive asymptomatic high-risk individuals (HRI) who consented to be part of the 
CAPS 3 study and underwent an endoscopic ultrasound examination at 1 of the 5 
participating centers (Johns Hopkins Hospital (Baltimore, Maryland), Mayo Clinic 
(Rochester, Minnesota), University of California (Los Angeles, California), Dana Farber 
Cancer Institute (Boston, Massachusetts), and MD Anderson Cancer Center (Houston, 
Texas)) were screened for eligibility.  HRIs included those with Peutz–Jeghers syndrome 
(PJS), familial breast-ovarian cancer patients with at least 1 affected first- or second-
degree relative with pancreatic ductal adenocarcinoma (PC), and relatives of patients 
with familial pancreatic cancer (FPC) with at least 1 affected first-degree relative.  
Exclusion criteria included:  inability to provide informed consent, prior pancreas 
screening, Karnofsky performance status of less than 60, any suspicion of pancreatic 
disease, prior pancreas surgery, severe medical illness, bleeding diathesis or 
thrombocytopenia, renal insufficiency, allergic reaction to radiographic contrast 
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material, morbid obesity, severe claustrophobia, and upper gastrointestinal tract 
obstruction.   
 
Endoscopic ultrasound:   
Advanced endoscopists with expertise in EUS performed all of the procedures.   EUS 
imaging was performed using a mechanical or electronic radial array (GFUM20, 
GFUE160-AL5; Olympus Corporation, Center Valley, PA) and/or a linear array 
echoendoscope (CFUC140P, SSD-Alpha5 or Alpha10; Olympus Corporation). While some 
HRI had only one radial or linear EUS examinations, the majority of the participants 
underwent tandem radial and linear EUS in a randomized order.  Random allocation 
sequence was performed using a random-numbers table and sequentially numbered, 
opaque, sealed envelopes at each site.  
 
Pancreatic lesion was defined as a cystic lesion, a solid lesion, or a dilated main 
pancreatic duct.  The size and location of each lesion were identified on a pancreas map 
for precise documentation for each EUS examination (Appendix 3). 
 
Statistical methods: 
The chi-square, Fisher exact test, t test, and Wilcoxon rank-sum test were performed for 
categoric and numeric variables, where appropriate, to compare characteristics. Two-
tailed P values less than 0.05 were considered statistically significant.  All statistical 
44 
     
analyses were performed using the Stata software package, version 11 (Stata Corp, 




Table 1 summarizes the baseline characteristics of the high-risk individuals (HRIs) 
included in the study.  A total of 278 asymptomatic HRIs were enrolled with mean age of 
56.1 years (range 25.6-86.5 years), over 70% of whom were over the age of 50.   The 
HRIs were predominantly Caucasians (92%) and a part of the familial PC risk group 
(90%).  The remaining 10% were mutation carriers.   Of the 278 HRIs, 54 had only one 
radial or linear EUS; 25 HRIs had radial EUS examination alone and 29 HRIs had linear 
EUS examination alone.  The remaining 224 (80.6%) HRI had tandem radial and linear 
EUS in a randomized order (Figure 1).    
 
Using a per-patient analysis, the prevalence of > 1 pancreatic lesions was 43.2% 
(120/278). In these 120 HRIs with pancreatic lesions, defined as a cystic lesion, a solid 
lesion, or a dilated main pancreatic duct, the majority had cystic lesions (99/120; 82.5%) 
with mean size of 0.8cm (range 0.1-8cm). In HRIs who underwent a single EUS exam, 
linear EUS detected more pancreatic lesions than radial EUS (65.4% vs 39.5%, p=0.01).  
In those who had 2 EUS examinations in tandem, 16 of the 224 (7.1%) HRIs had lesions 
missed during the initial EUS. Of these 16 HRIs with missed lesions, 11 (9.8%) had radial 
followed by linear (radial/linear) EUS and 5 (4.5%) had linear followed by radial 
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(linear/radial) EUS (p=0.03).   The missed lesions were distributed throughout the 
pancreas (p=N.S.).  The average size of the lesions missed by radial EUS was small (mean 
0.57cm, range 0.3-1.2cm) and similar (p=0.63) to those missed by linear EUS (mean 
0.47cm, range 0.3-0.6cm).   
 
In the 224 HRIs who underwent tandem EUS examinations, there were 229 pancreatic 
lesions identified in total.  In a per-lesion analysis, 109 lesions were detected by any EUS 
in the radial/linear group. The first radial EUS yielded 73/109 lesions (67%) and the 
second linear EUS yielded additional 36 lesions. In the linear/radial group, a total of 120 
lesions were detected. The first linear EUS detected 99/120 lesions (82.5%) and the 
second radial EUS yielded additional 21 lesions (Figure 2). Hence, the incremental 
detection rate for a pancreatic lesion during a second exam with the linear EUS was 
significantly higher than that for the radial EUS (33% vs 17.5%, p= 0.007).  
 
When all of the radial EUS examinations are combined, regardless of whether it was 
performed as a single procedure, or as a first case or second case of a tandem 
procedure, radial EUS yielded 173 of 262 (66.0%) total pancreatic lesions.  For linear EUS 





     
Endoscopic endosonography (EUS) is a powerful imaging technique in the evaluation of 
pancreatobiliary disease and lesions.  With 2 distinct designs in echoendoscope, radial 
array and linear array echoendoscope,9, 10  the choice of which to use for 
pancreatobiliary imaging have been left to the discretion and preference of the 
individual endosonographer.  Over the past 10-15 years, there has been a shift in 
increased use of linear EUS for pancreatic imaging, even in those cases where fine 
needle aspiration (FNA) is not indicated.11, 12   Anecdotally, some endosonographers feel 
that linear EUS provides superior quality and more complete imaging of the pancreas.19  
To the best of our knowledge, no prior studies have shown the postulated superior 
ability of the linear EUS to image the pancreas.   
 
This study validates the current trend in increasing preference for the curvilinear array 
echoendoscope for pancreatic imaging.  We have shown that linear array 
endosonography detected more pancreatic lesions when compared to radial array 
endosonography in a cohort of asymptomatic high-risk individuals (HRIs) undergoing 
screening program through the multi-center American Cancer of the Pancreas Screening 
(CAPS 3) Consortium study.    
 
Furthermore, akin to the field of screening colonoscopy and adenoma detection, there 
is a “second-pass effect” with additional pancreatic lesions detected with the second 
EUS exam in a tandem study for both the radial and linear EUS.  However, this effect 
was significantly greater when the linear EUS was used as the second imaging modality 
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after the initial radial EUS examination.  When the initial screening examination was 
performed with radial array echoendoscope, 1/3 of the pancreatic lesions were missed; 
when the initial screening examination was performed with linear EUS, less than 20% of 
the pancreatic lesions were missed.  Reassuringly, all of missed lesions were relatively 
small in size and well-distributed throughout the pancreas.   Overall, the per-patient 
miss rate for pancreatic lesions in HRI was significantly lower for linear EUS compared to 
radial EUS.   
 
There are several strengths of the current study.  It is an embedded study within a large, 
multi-center study involving 5 centers using site-specific EUS equipments, which speaks 
to its generalizability across multiple academic facilities.  Second, the study was 
randomized in the order of EUS examination in the tandem study, which each patient 
serving as his/her own control in terms of participant variables.  Third, the cohort 
involved asymptomatic HRIs enrolled in a screening program, which consequently 
required complete imaging of the pancreas in a standardized fashion, instead of 
focusing on a target lesion. 
 
Our study also had several limitations.  All of the EUS examinations were performed only 
by expert endosonographers.  Furthermore, majority of the pancreatic lesions detected 
in the study could not be verified by pathology since most were not surgically resected.  
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In conclusion, the results of our study suggest that linear EUS should be the 
echoendoscope of choice when imaging the pancreas, even when biopsy or therapeutic 
interventions is not expected.   
  
49 
     
References: 
1. Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, Topazian M, 
Takahashi N, Fletcher J, Petersen G, Klein AP, Axilbund J, Griffin C, Syngal S, 
Saltzman JR, Mortele KJ, Lee J, Tamm E, Vikram R, Bhosale P, Margolis D, Farrell 
J, Goggins M. Frequent detection of pancreatic lesions in asymptomatic high-risk 
individuals. Gastroenterology 2012;142:796-804; quiz e14-5. 
2. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick 
RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M. 
International Cancer of the Pancreas Screening (CAPS) Consortium summit on 
the management of patients with increased risk for familial pancreatic cancer. 
Gut 2013;62:339-47. 
3. Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, Fishman 
EK, Brune K, Axilbund J, Griffin C, Ali S, Richman J, Jagannath S, Kantsevoy SV, 
Kalloo AN. Screening for early pancreatic neoplasia in high-risk individuals: a 
prospective controlled study. Clin Gastroenterol Hepatol 2006;4:766-81; quiz 
665. 
4. Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, van Eijck CH, Cats A, 
Kuipers EJ, Nio Y, Fockens P, Bruno MJ. The yield of first-time endoscopic 
ultrasonography in screening individuals at a high risk of developing pancreatic 
cancer. Am J Gastroenterol 2009;104:2175-81. 
5. Vasen HF, Wasser M, van Mil A, Tollenaar RA, Konstantinovski M, Gruis NA, 
Bergman W, Hes FJ, Hommes DW, Offerhaus GJ, Morreau H, Bonsing BA, de Vos 
50 
     
tot Nederveen Cappel WH. Magnetic resonance imaging surveillance detects 
early-stage pancreatic cancer in carriers of a p16-Leiden mutation. 
Gastroenterology 2011;140:850-6. 
6. Ludwig E, Olson SH, Bayuga S, Simon J, Schattner MA, Gerdes H, Allen PJ, 
Jarnagin WR, Kurtz RC. Feasibility and yield of screening in relatives from familial 
pancreatic cancer families. Am J Gastroenterol 2011;106:946-54. 
7. Verna EC, Hwang C, Stevens PD, Rotterdam H, Stavropoulos SN, Sy CD, Prince 
MA, Chung WK, Fine RL, Chabot JA, Frucht H. Pancreatic cancer screening in a 
prospective cohort of high-risk patients: a comprehensive strategy of imaging 
and genetics. Clin Cancer Res 2010;16:5028-37. 
8. Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, Slater EP, 
Heverhagen JT, Gress TM, Rothmund M, Bartsch DK. Five years of prospective 
screening of high-risk individuals from families with familial pancreatic cancer. 
Gut 2009;58:1410-8. 
9. Byrne MF, Jowell PS. Gastrointestinal imaging: endoscopic ultrasound. 
Gastroenterology 2002;122:1631-48. 
10. Tierney WM, Adler DG, Chand B, Conway JD, Croffie JM, DiSario JA, Mishkin DS, 
Shah RJ, Somogyi L, Wong Kee Song LM, Petersen BT. Echoendoscopes. 
Gastrointest Endosc 2007;66:435-42. 
11. Irisawa A. Current role of radial and curved-linear arrayed EUS scopes for 
diagnosis of pancreatic abnormalities in Japan. Dig Endosc 2011;23 Suppl 1:9-11. 
51 
     
12. Noh KW, Woodward TA, Raimondo M, Savoy AD, Pungpapong S, Hardee JD, 
Wallace MB. Changing trends in endosonography: linear imaging and tissue are 
increasingly the issue. Dig Dis Sci 2007;52:1014-8. 
13. Gress F, Savides T, Cummings O, Sherman S, Lehman G, Zaidi S, Hawes R. Radial 
scanning and linear array endosonography for staging pancreatic cancer: a 
prospective randomized comparison. Gastrointest Endosc 1997;45:138-42. 
14. Jamil LH, Gill KR, Gross S, Crook J, Raimondo M, Woodward T, Wallace MB. 
Radial versus linear EUS in evaluation of suspected pancreatic cancer:  is it 
sufficient to use linear EUS alone? Gastrointest Endosc 2009;69:S266. 
15. Matthes K, Bounds BC, Collier K, Gutierrez A, Brugge WR. EUS staging of upper GI 
malignancies: results of a prospective randomized trial. Gastrointest Endosc 
2006;64:496-502. 
16. Siemsen M, Svendsen LB, Knigge U, Vilmann P, Jensen F, Rasch L, Stentoft P. A 
prospective randomized comparison of curved array and radial echoendoscopy 
in patients with esophageal cancer. Gastrointest Endosc 2003;58:671-6. 
17. Rosch T. Endoscopic ultrasonography in pancreatic cancer. Endoscopy 
1994;26:806-7. 
18. Catalano MF, Kaul V, Hernandez LV, Pezanoski JP, Guda NM, Ramasamy D, 
Samavedy R, Geenen JE. Diagnosis of Chronic Pancreatitis (CP) By Endoscopic 
Ultrasound (EUS) - Radial Vs. Linear Endosonography (EUS). Gastrointest Endosc 
2008;67:AB208. 
52 
     
19. Stevens T, Zuccaro G, Jr., Dumot JA, Vargo JJ, Parsi MA, Lopez R, Kirchner HL, 
Purich E, Conwell DL. Prospective comparison of radial and linear endoscopic 
ultrasound for diagnosis of chronic pancreatitis. Endoscopy 2009;41:836-41. 
20. Heresbach D, Barrioz T, Lapalus MG, Coumaros D, Bauret P, Potier P, Sautereau 
D, Boustiere C, Grimaud JC, Barthelemy C, See J, Serraj I, D'Halluin PN, Branger B, 
Ponchon T. Miss rate for colorectal neoplastic polyps: a prospective multicenter 
study of back-to-back video colonoscopies. Endoscopy 2008;40:284-90. 
21. Hixson LJ, Fennerty MB, Sampliner RE, Garewal HS. Prospective blinded trial of 
the colonoscopic miss-rate of large colorectal polyps. Gastrointest Endosc 
1991;37:125-7. 
22. Munroe CA, Lee P, Copland A, Wu KK, Kaltenbach T, Soetikno RM, Friedland S. A 
tandem colonoscopy study of adenoma miss rates during endoscopic training: a 
venture into uncharted territory. Gastrointest Endosc 2012;75:561-7. 
23. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp 
miss rate determined by tandem colonoscopy: a systematic review. Am J 
Gastroenterol 2006;101:343-50. 
24. Rex DK, Cutler CS, Lemmel GT, Rahmani EY, Clark DW, Helper DJ, Lehman GA, 
Mark DG. Colonoscopic miss rates of adenomas determined by back-to-back 
colonoscopies. Gastroenterology 1997;112:24-8. 
25. Bensen S, Mott LA, Dain B, Rothstein R, Baron J. The colonoscopic miss rate and 
true one-year recurrence of colorectal neoplastic polyps. Polyp Prevention Study 
Group. Am J Gastroenterol 1999;94:194-9. 
53 
     
26. Kasugai K, Miyata M, Hashimoto T, Todoroki I, Tsutsui S, Nagase F, Wada Y, Sato 
M, Takahashi K. Assessment of miss and incidence rates of neoplastic polyps at 
colonoscopy. Dig Endosc 2005;17:44-49. 
27. Matsushita M, Hajiro K, Okazaki K, Takakuwa H, Tominaga M. Efficacy of total 
colonoscopy with a transparent cap in comparison with colonoscopy without the 
cap. Endoscopy 1998;30:444-7. 
28. Rex DK, Chadalawada V, Helper DJ. Wide angle colonoscopy with a prototype 
instrument: impact on miss rates and efficiency as determined by back-to-back 
colonoscopies. Am J Gastroenterol 2003;98:2000-5. 
29. Harrison M, Singh N, Rex DK. Impact of proximal colon retroflexion on adenoma 
miss rates. Am J Gastroenterol 2004;99:519-22. 
30. Leufkens AM, DeMarco DC, Rastogi A, Akerman PA, Azzouzi K, Rothstein RI, 
Vleggaar FP, Repici A, Rando G, Okolo PI, Dewit O, Ignjatovic A, Odstrcil E, East J, 
Deprez PH, Saunders BP, Kalloo AN, Creel B, Singh V, Lennon AM, Siersema PD. 
Effect of a retrograde-viewing device on adenoma detection rate during 




     
Table 1:  Baseline High-Risk Individuals (HRI) Characteristics 
 
 Total (N=278) 
Risk Group 
- Familial PC 
- BRCA2 + PC relative 







- African American 
- Native American 













Mean:  56.1 years (range 25.6-86.5) 








     


























     
 








224 HRI tandem EUS with 
229 total pancreatic lesions 
109 lesions in 
radial/linear EUS group 
Radial EUS 73/109 lesions 
(67%) 
Linear EUS additional 36 
lesions 
120 lesions in 
linear/radial EUS group 
Linear EUS 99/120 lesions 
(82.5%) 
Radial EUS additional 21 
lesions 
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Chapter 3:  Novel filter clot cellblock technique is associated with increased sample 




     
Introduction 
 
Endoscopic ultrasound with fine needle aspiration (EUS-FNA) has become a powerful 
tool in diagnosing and obtaining pre-operative cytologic samples of enlarged lymph 
nodes and lesions in the upper gastrointestinal tract, pancreas, and rectum.  Overall 
diagnostic rates of EUS-FNA range from 52% to 92% depending upon the site of tissue 
acquisition.1-16  Diagnostic rates also vary according to procedure indication and type of 
lesion. EUS-FNA has sensitivity of approximately 75-90% and specificity of nearly 100% 
for the diagnosis of a malignant-appearing pancreatic mass lesions.1, 4-6, 8, 11, 12, 16   EUS-
FNA has sensitivity of 72-100%, specificity of 93-100%, and accuracy rate of 86-100% for 
the evaluation of lymphadenopathy.2, 3, 7, 9, 11-16  However, for gastrointestinal 
submucosal lesions, EUS-FNA has a lower sensitivity of 50-60%, specificity of 25-100%, 
and accuracy rate of 38-81%.11-13, 16   
 
The variability of the diagnostic rates of EUS-FNA may, in part, be due to the limited 
cellularity and loss of the architectural features in the EUS-FNA samples.  One potential 
method of improving the diagnostic yield of EUS-FNA is the filter clot cellblock 
technique.  
 
The filter clot (FC)  technique has been used by Japanese pulmonologists for processing 
ultrasound-guided transbronchial needle aspirate (TBNA) samples 17. This technique was 
introduced to our institution in 2009 for pulmonary indications but has yet been studied 
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for potential use in gastrointestinal indications.  Preliminary analysis of the diagnostic 
yield of TBNA for mediastinal lesions at our institution showed a significant 
improvement in the cellularity of the samples processed using the filter cellblock 
technique, allowing for immunohistochemical staining for diagnostic and prognostic 
tumor markers (personal communication).  The aim of our study was to compare the 
diagnostic yield and accuracy of the filter clot (FC) cellblock technique to the standard 
(STN) cytological cellblock technique of processing EUS-FNA samples. 
 
Patients and Methods 
 
Study Design, Setting, Participants 
This single center non-randomized retrospective concurrent cohort study was 
conducted in a tertiary care academic medical center. Using data from our 
cytopathology and EUS databases, a retrospective review was performed for 
consecutive patients who underwent EUS-FNA with on-site cytopathologic evaluation at 
The Johns Hopkins Hospital from January 2009 to February 2010 for:  (1) pancreatic solid 
or solid/cystic mass lesions, (2) mediastinal or intra-abdominal lymph nodes or soft 
tissue masses, and (3) gastrointestinal submucosal masses.  Patients were excluded if 
the pancreatic lesion was entirely cystic with no solid component.  All patients gave 
written informed consent for standard of care EUS-FNA.  The study was approved by the 
Johns Hopkins Institutional Review Board for Human Research. 
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All pertinent patient demographics, endoscopic (indication for FNA, lesion size) data, 
surgical pathology, cytopathology, and long-term clinical follow-up were abstracted 
from electronic patient records.   
 
EUS-FNA 
All EUS-FNA examinations were performed by one of 3 experienced endosonographers 
with intravenous propofol sedation and monitored anesthesia care using linear 
echoendoscopes.  All procedures had routine on-site cytological evaluation by 
experienced cytotechnologists for preliminary sample processing and preliminary 
assessment of sample adequacy to help guide specimen acquisition.  Standard 
technique for EUS-FNA sampling was used.  A 22-, 25-, or 19- gauge FNA needle (Cook 
Medical, Bloomington, IN) was inserted into the lesion and 10 cc of suction applied with 
“to-and-fro” movement of the needle tip.  The choice of needle size and the total 
number of needle passes were determined by the endoscopist based upon the target 
lesion type, location, and size.  If sampling with the initial FNA needle did not lead to 
adequate cytological material, another FNA needle of either higher or lower gauge was 
used at the discretion of the endoscopist.  Typically, a minimum of 4 needle aspirates 
were obtained for lymph nodes and 6 FNA passes were obtained for pancreatic masses, 
unless adequate material was present in prior passes.  
 
EUS-FNA Cell Block Techniques 
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The EUS-FNA samples were processed in one of two ways: standard (STN) technique or 
filter clot cellblock technique.  At our institution, the “standard technique” has been 
utilized since 1996 when EUS-FNA was introduced.  It involves using an air-filled syringe 
attached to the FNA needle to express a few drops of each sample onto glass slides for 
direct smears.  One set of direct smears was air-dried and stained with the Diff-Quik 
stain for on-site evaluation; another set was immediately fixed in 95% ethanol and 
subsequently stained with the Papanicolaou stain.  The FNA needle is then rinsed with 
Hank’s balanced salt solution (~1-2cc) and the material is collected in a sterile conical 
centrifuge tube.  This process is repeated after each FNA attempt.  The steps are 
performed in the EUS endoscopy room.  After all of the samples are collected in the 
tube, the rinse is centrifuged in the cytology laboratory to collect the pellet.  The 
supernatant is then discarded and the pellet is scraped off and submitted for cell block.  
The cellblock is fixed in 10% neutral buffered formalin. The cellblock is then examined 
after standard processing of slides and H&E staining. The final diagnosis is made after 
examination of the slides with cytological FNA smears and cellblock specimen.  
 
The filter clot (FC) cellblock technique was initiated at our institution in January 2009. It 
involves using the stylet passed through the FNA needle to express a few drops of the 
sample onto the glass slide for bedside smears.  A 1” x 1” piece of filter paper is placed 
on top of a second glass slide.  The remaining sample is pushed out from the FNA needle 
with the stylet onto the filter paper, allowing the needle tip to build up a cone-shaped 
mound of tissue and blood coagulum.  This process is repeated after each FNA attempt.  
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The tissue coagulum collected on the filter paper at the end of the procedure (Figure 1) 
is entirely submitted for cellblock and is fixed in 10% neutral buffered formalin. The 
formalin-fixed clot is then processed using standard techniques for preparation of 
stained slides for pathologic examination. The final diagnosis is made after examination 
of the slides with cytological FNA smears and cellblock specimen. 
 
The primary endpoints of the study were:  (1) sample adequacy, which was defined as 
the percentage of STN and FC samples with material adequate for diagnosis and (2) 
diagnostic accuracy, which was defined as the percentage of accurate diagnosis attained 
on FNA samples in patients with surgical pathology and/or long-term clinical follow-up 
as the reference standard.  Secondary endpoints were sample adequacy and diagnostic 




The performance characteristics of the FNA sample processing techniques were 
calculated for all patients and by indication using the final diagnosis based upon surgical 
pathology or the results of long-term clinical follow-up after 6 months as the gold 
standard.  For patients who did not undergo surgical resection, final diagnosis of 
malignancy was made if patient had cytology specimen diagnostic for malignancy with 
clinical progression or death from the malignancy.   For patients deemed to have a 
benign process by EUS-FNA who did not undergo surgical resection, they were followed 
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clinically for at least 6 months, in accordance with other previous studies in this field.  
The patients needed to be without any clinical indication of malignant process, with no 
evidence of disease progression and/or with resolution of imaging abnormality during 
the clinical follow-up period (based on patient record review) for the diagnosis of benign 
disease.  
 
Fisher’s exact test and univariate logistic regression analysis were performed prior to 
multivariate logistic regression to analyze the effect of the filter cellblock technique on 
sample adequacy and diagnostic accuracy.  All statistical analyses were performed using 




During the study period, 320 EUS-FNA examinations for pancreatic mass lesions, lymph 
nodes, soft tissue masses, or gastrointestinal submucosal masses were performed.  A 
total of 311 patients (mean age of 62.3 +/- 12.9 years) were included in the study. One 
hundred fifty five were males (49.8%).  Of the 320 total EUS-FNA cases, 78 samples were 
processed using the FC cellblock technique (24.4%) while the remaining 242 (75.6%) 
were processed using the standard technique.  
 
Table 1 details the indications for EUS-FNA procedures during the study period. The 
most common indication for the EUS-FNA was solid pancreatic mass (n=123, 38.4%).  
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Pancreatic cyst with a solid component or mural nodule (n=91, 28.4%) was the second 
most common indication.  For these lesions, the targets of the tissue sampling were the 
solid components or mural nodules within the cystic portions of the lesion. Other 
indications included lymph nodes (n=56, 17.5%), submucosal mass lesions (n=15, 4.7%), 
and miscellaneous indications (pancreatic and biliary stricture and adrenal mass).  One 
hundred sixty nine (53%) of the 320 target lesions were small (< 3 cm).  The size of the 
lesions targeted for EUS-FNA ranged from 3.5 mm to 7.4 cm (mean of 2.6 cm + 1.4 cm).  
 
Sample Adequacy 
Table 2 shows the comparison of the STN and FC cellblock techniques for sample 
adequacy.  Two hundred forty of the 320 EUS FNA samples (75%) were deemed to have 
adequate cellularity to make a cytological diagnosis by final cytological evaluation. 
Overall, significantly more FC samples had adequate cellularity compared to STN 
technique (87% versus 71%, p=0.004).  When results were analyzed by EUS-FNA 
indication (lesion type) (Table 2), there were numerical differences between FC and STN 
technique adequacy rates, but these did not reach statistical significance. 
 
Overall, the EUS-FNA samples processed with the FC cellblock technique were more 
likely to have a higher rate of sample adequacy when compared to the STN technique 
(OR 2.77, 95% CI 1.35-5.68, p=0.006).  Figures 2 and 3 show representative cytological 
samples obtained during EUS-FNA for evaluation of solid pancreatic masses.  The FC 
cellblock technique was also independently associated with improved sample adequacy 
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of EUS-FNA with an odds ratio of 2.94 (95% CI 1.26-6.90, p=0.013), even after controlling 
for the lesion size and the lesion type (indication for the EUS-FNA) (Table 3). 
 
Diagnostic Accuracy 
The final diagnosis was confirmed by pathologic examination of the resected specimen 
and/or clinical and radiology follow-up for at least 6 months in 171 of the 320 EUS-FNA 
procedures. In these samples, the FC cellblock technique was associated with a 
significantly higher overall accuracy of EUS-FNA diagnostic samples compared to the 
STN technique (92% versus 79%, respectively, p =0.03).  The likelihood of an accurate 
diagnosis for all target lesions was almost 3 times greater when the FC cellblock 
technique was used (OR 2.96; 95% CI 1.06-8.24; p=0.04).  
 
After stratifying by lesion type (indication for EUS-FNA), there were numerical increases 
in the diagnostic accuracy rate using the FC technique over the standard technique for 
each subgroup. The greatest potential difference in diagnostic accuracy between the FC 
and STN techniques was for lymph nodes (75-92%, p= 0.05).  After controlling for the 
type of lesion, the FC cellblock technique was independently associated with improved 





     
Endoscopic ultrasound with fine needle aspiration (EUS-FNA) is an important tool for 
obtaining tissue for diagnosis of pancreatic lesions, mediastinal and intra-abdominal 
lymphadenopathy and soft tissue masses, and gastrointestinal submucosal lesions.  
With relatively low rates of complications and tumor seeding, it has increasingly become 
the technique of choice for pre-surgical and non-surgical tissue acquisition.  However, 
the diagnostic yield of EUS-FNA varies by indication and can be relatively low when 
sampling submucosal masses and indeterminate pancreatic masses.1-16  Hence, here is 
continued interest in improving techniques to increase the overall sample adequacy and 
diagnostic accuracy rate of EUS-FNA. 
 
We describe the first application of the FC cellblock technique for processing EUS-FNA 
samples from gastrointestinal, pancreatic, and mediastinal lesions.  The results of our 
study suggest that the FC technique of processing EUS-FNA samples is associated with 
increased overall sample adequacy and diagnostic accuracy rates of 87% and 92%, 
respectively, when compared to the STN cytological technique.   Importantly, EUS-FNA 
specimens that were processed with the FC cellblock technique were more likely to be 
diagnostic and associated with an accurate final diagnosis. When the sample adequacy 
and accuracy of FC and STN cellblock samples were compared by lesion type, there were 
differences potentially favoring the FC technique but these were not statistically 
significant. This might be explained by the limited sample sizes for each type of lesion 
(EUS FNA indication), the heterogeneous patient population, variability in FNA 
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technique and needle type, non-prospective data collection, and other unknown 
confounding factors. 
 
The FC cellblock technique may provide several advantages over the STN technique for 
processing EUS FNA samples.  Multiple manipulations of the samples are required in the 
standard technique, and each step could potentially lead to some small cell loss 
affecting overall yield.  First, an air-filled syringe is used to express the sample from the 
FNA needle at our institution, which may be problematic as the material could spray out 
in an uncontrolled manner and may adversely influence yield.  Each EUS-FNA passes are 
collected with a rinse of Hank’s balanced salt solution which dilutes the concentration of 
the cells in the tube, and the solution then needs to be concentrated in a centrifuge.  
Second, the supernatant is discarded after centrifugation and some cells may be lost 
during this process.  Third, cells could also be lost during the actual pellet transfer, since 
the technician has to physically scrape the pellet from the bottom of the centrifuge tube 
to transfer the pellet to the cellblock. With the FC technique, the cellular material 
remains embedded in the blood clot and is never disassociated from the coagulum. 
 
Another potential advantage of the FC cellblock technique is that it is technically easy, 
requiring no additional specialized skills for the assistants or cytology technician.  No 
additional cytology or surgical pathology equipment is required, including a centrifuge.  
Although our study did not evaluate procedure time, the preparation of the tissue 
coagulum was accomplished quickly within a few minutes and there seemed to be no 
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significant increase in the overall EUS procedure time and in-room sample processing 
time using the filter clot cellblock technique.   The FC cellblock technique may also 
decrease the need for on-site cytological evaluation if it can improve the overall yield of 
the EUS-FNA sample.   
 
Our study has some limitations.  This was a single-center, non-randomized retrospective 
study at a tertiary care American medical institution.  Hence, we cannot control for 
important factors that influence the outcomes of EUS-FNA, such as number of needle 
passes and gauge of needle.  Furthermore, there was no pathologic confirmation for the 
non-surgical cases, relying on long-term clinical follow-up of at least 6 months to 
discriminate between benign and malignant lesions.  This limitation is inherent to all 
diagnostic tests performed on non-surgical patients that rely upon pathologic diagnosis 
as the reference standard. Our study did not include enough patients to demonstrate a 
potential difference between the STN and CB techniques for different EUS-FNA 
indications, but there were interesting trends that need further study. Finally, the 
overall negative predictive value of EUS-FNA at our institution was relatively low during 
the study period, possibly due to factors that influence disease prevalence, such as case 
mix and selective use of EUS-FNA for indeterminate masses as opposed to routine 
application prior to surgery.  Despite its limitations, this study provides data on the 
potential for the FC cellblock technique as an alternative method for processing EUS-
FNA samples.    
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In conclusion, the use of the filter clot technique for processing EUS-FNA samples was 
associated with an increased sample adequacy and diagnostic accuracy compared to 
standard cytological technique.  By increasing specimen cellularity, the filter clot 
technique may potentially improve the feasibility for immunohistochemical staining and 
other studies for specific molecular markers that are important for tumor diagnosis, 
treatment response, and prognosis.    
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Table 1:  Indications for EUS-FNA 
 
Indications for EUS-FNA N (%) Mean size + SD (in cm) 
Solid pancreatic mass 123 (38.4%) 2.94 + 0.14 
Cystic/solid pancreatic mass 91 (28.4%) 2.29 + 0.14 
Lymph nodes 56 (17.5%) 1.91 + 0.19 
Submucosal mass 15 (4.7%) 2.57 + 0.33 
Miscellaneous indications (including 
pancreatic and biliary stricture on 
imaging, and adrenal mass).   
35 (10.9) 3.28 + 0.35 




     
Table 2:  Percent Sample Adequacy of EUS-FNA in 320 Lesions 
 
Indications for EUS-FNA Standard Technique Filter Cellblock Technique 
Solid pancreatic mass 86% 90% 
Cystic/solid pancreatic mass 63% 75% 
Lymph nodes 70% 94% * 
Submucosal mass 44% 83% 
Overall  71% 87% ** 
 
* p=0.05  ** p=0.004   
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Table 3: Sample Adequacy of EUS-FNA in 320 Lesions 
 
Variable  Adjusted Odds 
Ratio 
95% Confidence Interval p-value 
Filter cellblock 
technique 
2.94 1.26 - 6.90 0.013 
Lesion size  1.17 0.94 - 1.46 0.161 




     
  
Table 4:  Diagnostic Accuracy of EUS-FNA in 171 Lesions with Final Diagnosis 
 
Indications for EUS-FNA Standard Technique Filter Cellblock Technique 
Solid pancreatic mass 81% 94% 
Cystic/solid pancreatic mass 73% 88% 
Lymph nodes 75% 92% * 
Submucosal mass 60% 75% 
Overall  79% 92% ** 
 














     
 
 
Figure 2A. Representative cellblock using the standard (STN) technique (10x) of 





     
 
 
Figure 2B. Representative cellblock using the filter clot (FC) cellblock technique (10x) of 





     
 
 
Figure 3A. Representative cellblock using the standard (STN) technique (10x) of 





     
 
 
Figure 3B. Representative cellblock using the filter clot (FC) cellblock technique (10x) of 




     
Chapter 4: DPC4 status of EUS-FNA samples in patients with pancreatic 













Adapted with permission from:  Shin EJ, Khashab M.  The role of endoscopy in the 
treatment, management, and personalization of pancreatic cancer.  Curr Probl Cancer. 2013 
Sep-Oct;37(5):293-300  
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Introduction: 
 
Despite significant advances in medicine over the past decade, pancreatic 
adenocarcinoma remains one of the deadliest diseases being the fourth leading cause of 
cancer-related deaths in the United States for both males and females, with an 
estimated 45,220 new cases and 38,460 deaths in 2013.1  In stark contrast to the death 
rates for other leading causes of cancer death (lung, colorectal, breast, and prostate), 
which have declined since 2003, the mortality rate from pancreatic adenocarcinoma has 
increased during the same time period.  Therefore, early detection, diagnosis, and 
accurate stratification of patients with pancreatic mass lesions are paramount in 
providing timely, optimal care.  As such, endoscopic interventions are emerging as 
increasingly important diagnostic and therapeutic modalities in the management of 
patients with pancreatic cancer.   
 
Personalization of Pancreatic Cancer Therapy 
There has been a growing interest in personalized medicine, especially in the field of 
cancer treatment.  It is now routine practice in lung, colorectal, breast, and prostate 
cancer to utilize the biomarker status of the primary tumor to tailor oncologic therapies 
to the individual patient.  Prognostic biomarkers “provide insight into the natural history 
of disease, including survival and recurrence pattern,” while predictive biomarkers 
“predict response to treatment.”2, 3  Molecular profiling of tumors to improve treatment 
and outcome is an emerging concept in pancreatic cancer.  Multiple prognostic 
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biomarkers (MUC-1, MSLN, SMAD4/DPC4, FOSB, KLF6, NFKB12, ATP4A, GSG1, and 
SIGLEC11) and predictive biomarkers (HuR, HENT1, RRMI, ERCC1, and SPARC) have been 
investigated in pancreatic adenocarcinoma, with promising initial results.   
 
DPC4 (a.k.a. SMAD4) is a tumor suppressor gene inactivated in ~55% of pancreatic 
ductal adenocarcinomas4 and its protein product functions in the TGF beta/Smad 
signaling pathway.  Dpc4 immunolabeling has been shown to be an accurate predictor 
of DPC4 gene status.5  Previous studies have shown an intriguing association between 
DPC4 gene mutation status of primary pancreatic cancers and patient outcome.6-9  In an 
autopsy series, DPC4 gene status of the primary tumor appears to correlate with pattern 
of recurrence and disease failure in patients with pancreatic adenocarcinoma.8  Those 
with DPC4 inactivation, by either deletion or mutation of the gene, correlated with a 
widespread metastatic disease phenotype, while those with an intact DPC4 status 
correlated with a locally advanced/oligometastatic disease phenotype.6-9  The ability to 
identify the disease phenotype may have an impact on tailoring clinical management.  
For example, patients with loss of DPC4 expression may benefit from systemic rather 
than locoregional therapy given the higher risk of widely metastatic disease recurrence, 
while patients with intact DPC4 status may benefit from locoregional control with 
adjuvant chemoradiation and cytoreductive treatment.10, 11  Therefore, it will become 
increasingly more important to obtain diagnostic samples adequate for biomarkers 
studies in patients with pancreatic mass lesions.  
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Role of Endoscopic Ultrasound (EUS) in Diagnosis and Obtaining Samples for Biomarker 
Studies  
There are several methods of obtaining diagnostic samples in patients with pancreatic 
masses:  endoscopic ultrasound-fine needle aspiration (EUS-FNA), percutaneous image-
guided tissue sampling by computed tomography (CT) or ultrasound (US), and surgical 
biopsy.  In patients with clearly resectable lesions on cross-sectional imaging, there still 
remains a debate whether a pre-operative biopsy is needed before undergoing 
definitive surgical resection, since a negative biopsy result in this setting would most 
likely not alter the plan for surgery.12, 13 Nonetheless, EUS changes management in 
about 5% of these patients with other etiologies for pancreatic masses (e.g., 
autoimmune pancreatitis, metastatic disease, and lymphoma). For all other patients 
with a pancreatic mass, biopsy sampling for definitive diagnosis is a critical first step in 
guiding clinical management.   EUS-FNA is becoming the preferred sampling technique 
in this population, as it is safe with diagnostic accuracy ranging between 62% and 96%, 
which can be improved with availability of on-site cytopathology to evaluate sample 
adequacy.13-17  EUS-FNA appears to be superior to image-guided (CT or US) biopsy in 
terms of accuracy of diagnosis of pancreatic cancer18 as well as safety since it carries a 
significantly lower risk of peritoneal seeding.19  There is also some evidence that EUS-




     
A major disadvantage of the standard EUS-FNA is that it often yields small cytologic 
samples without conservation of the tissue architecture, which can limit its use for 
immunohistochemical (IHC) and potential biomarker studies.21  Currently, adequate 
specimens of pancreatic tissue for molecular marker staining are often only obtained 
from surgical resection specimens.  Therefore, for patients deemed unresectable or for 
those patients who are unable to undergo surgery, Dpc4 immunolabeling of the tumor 
may be either impossible or only possible at autopsy.  However, there has been 
increasing interest in improving cellular yield of FNA samples for biomarker studies with 
new samples acquisition techniques, including filter clot (FC) cellblock technique, and 
new biopsy devices.   
 
The purpose of this study is to determine whether DPC4 gene status using EUS-FNA 
samples correlate with clinical outcome, which may help with pre-operative and pre-
treatment prognostic stratification of patients.  There are molecular markers which may 
have implications for overall prognosis of patients with pancreatic adenocarcinoma and 
in treatment strategy.  Evaluation of molecular marker status using EUS-FNA samples 
will enable testing of molecular markers to predict overall prognosis and may aid in 
strategizing individual treatment plan in patients in whom surgical resection is not 





     
Study Design and Study Population: 
This retrospective study was conducted in a single tertiary academic medical center.  
Using data from our cytopathology and clinical databases, a review was performed for 
patients who underwent EUS-FNA with a final diagnosis of pancreatic adenocarcinoma 
and were clinically followed at The Johns Hopkins Hospital (JHH).  Patients were 
excluded if patient did not have a EUS-FNA performed at JHH or did not have clinical 
follow-up with radiologic imaging examination (computed tomography (CT) and/or 
magnetic resonance imaging (MRI)) at JHH.  All patients gave written informed consent 
for the standard of care clinical EUS-FNA.  The study was approved by the Johns Hopkins 
Institutional Review Board for Human Research.    
 
All pertinent patient demographics, tumor size and pathology, DPC4 status, and clinical 
follow-up were abstracted from electronic patient records and/or cytopathology 
database.   
 
DPC4 Status Determination: 
Archival FNA material was obtained for confirmation of diagnosis of adenocarcinoma 
and evaluation of cellularity of the cell block (CB) preparation by an expert 
cytopathologist.  Only CB preparations with adequate tumor material were submitted 
for immunohistochemical (IHC) staining.  After IHC staining, the DPC4 status of each 
sample was agreed upon by 2 expert pathologists and graded as positive (intact/wild-
type) or negative (lost/mutated).   Figure 1 show a representative EUS-FNA sample 
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immunostained for DPC4 and graded as positive; Figure 2 show a representative EUS-
FNA sample graded as DPC4 negative.   
 
Statistical Analysis: 
The chi-square, Fisher exact test, t test, and Wilcoxon rank-sum test were performed for 
categoric and numeric variables, where appropriate, to compare characteristics. Two-
tailed P values less than 0.05 were considered statistically significant.  All statistical 
analyses were performed using the Stata software package, version 11 (Stata Corp, 





A total of 72 patient EUS-FNA samples were included in the study.  Forty-two of the 
patients were males (58.3%) with mean age of 63.9 +/- 11.0 years (range 43-84 years) 
and 45.8% were over the age of 65.  Majority of the patients were either Caucasian 
(70.8%) or African-American (22.2%).   DPC4 status was graded as positive in 32 and 
negative in 40 of the samples.  With regards to baseline patient demographics, there 
were no statistically different variables between the DPC4 positive and DPC4 negative 




     
In this cohort, the primary tumor was located predominantly in the head or uncinate 
process of the pancreas (76.4%), followed by the neck or body of the pancreas (15.3%) 
and the tail of the pancreas (8.3%).   Mean tumor size was 3.62 +/- 1.35 cm (range 1.77-
10.6), with 75% of patients having tumor size >3cm.  Only 21 (29.2%) of the patients 
included in this study were able to undergo surgical resection during their clinical 
course.  All patients included in the study had locally advanced, unresectable, or 
metastatic disease, as potentially surgically resectable patients typically underwent 
primary surgical intervention without routine pre-operative biopsy at our institution.  
Again, with respect to the clinical characteristics of the study population, there were no 
statistically significant differences between the DPC4 positive and DPC4 negative groups 
(Table 2). 
 
Patterns of Failure and Overall Survival: 
In total, 42 patients (58.3%) had evidence of metastatic disease during their clinical 
course.  Of those, 30 patients had DPC4 negative status in their tumor while 12 had 
DPC4 positive status (p=0.0013) (Table 3).  Univariate logistic regression analysis 
revealed that DPC4 positive status was associated with lower risk of having metastatic 
disease as the pattern of failure (OR 0.2, 95% CI 0.07-0.55, p=0.002).  Furthermore, 
DPC4 positive status was independently associated with decreased risk of metastatic 
disease progression (OR 0.19, 95% CI 0.06-0.60, p=0.004), even after controlling for age, 
gender, race, size of tumor, and location of tumor (Table 4).   Despite the differences in 
the pattern of failure, there was no statistically significant difference seen in the median 
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overall survival between the DPC4 positive and the DPC4 negative groups (12.6 vs 12.7 




Pancreatic adenocarcinoma is associated with abysmal outcomes, with overall 5-year 
survival rate of only 6%.  Traditionally, it was believed that patients with pancreatic 
cancer eventually died of progressive, widespread metastatic disease burden.  An 
autopsy study from our institution refuted this claim by showing that approximately 1/8 
of the patients died with zero evidence of metastasis.8  Furthermore, they were able to 
show that the biomarker status of the primary tumor highly correlated with the pattern 
of disease failure in the study population.  DPC4 gene is a mediator of canonical TGF-
beta signaling pathway. The loss of Dpc4 immunolabeling in the tumor appears to be 
associated with an increased risk of the patient developing widespread metastasis8 and 
poorer outcome following surgical resection.6, 22  One of the important potential clinical 
implications of this observed association of the DPC4 gene status and the differential 
pattern of failure in pancreatic adenocarcinoma is that patients with DPC4 expressing 
cancers may derive greater benefit from targeted localized therapy while patients with 
DPC4 non-expressing cancers may benefit more from systemic chemotherapy.8  
However, in order for biomarker studies to be useful in a clinical setting, it is crucial to 
obtain appropriate samples at the time of diagnosis.  Most studies published in the 
literature thus far evaluating biomarker studies in pancreatic cancer have used surgical 
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pathology specimens as pre-operative endoscopic ultrasound-guided fine needle 
aspirates (EUS-FNA) of the pancreas typically did not provide sufficient tissue for 
molecular marker analysis.  Therefore, for patients with unresectable pancreatic tumors 
or for those who were not surgical candidates, immunolabeling of the primary tumor 
was not routinely feasible.  However, recently, advances in new techniques and needle 
devices have improved the ability of EUS-FNA samples to be used for biomarker studies.   
 
The primary goal of the current study was to determine whether DPC4 status can 
predict the pattern of failure in patients with pancreatic adenocarcinoma using samples 
obtained from EUS-FNA.  To the best of our knowledge, this is the largest study to 
specifically address the feasibility and utility of using EUS-FNA samples to determine 
DPC4 status and its influence on the pattern of failure in patients with pancreatic 
adenocarcinoma.  We have shown that the DPC4 status of the primary tumor did appear 
to highly correlate with pattern of failure, with patients with DPC4 positive tumors 
significantly less likely to develop metastatic disease phenotype when compared to 
those with DPC4 negative tumors.  This association with decreased risk remained 
significant, even after controlling for multiple patient and tumor characteristics.  The 
results of this study appear to validate the clinical significance of Dpc4 immunolabeling 
status in diagnostic cytology specimens of pancreatic cancer patients as well as support 
the results from the seminal rapid autopsy study.8  Despite the differences in the 
pattern of disease progression, the DPC4 status did not appear to influence the overall 
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median survival duration, which, while thought-provoking, is consistent with another 
recently published study.23        
 
The main limitation of this study is the single-center retrospective nature of the study, 
which carries with it the inherent risk of biases which cannot be fully controlled for, 
even with multivariate analyses.  Furthermore, we could not standardize the clinical 
treatment course of the individual patients.  
 
Despite its limitations, this study provides important data that will be useful in planning 
future clinical studies evaluating the potential role of DPC4 status of the primary tumor 
at diagnosis in tailoring surgical and oncologic treatments in patients with pancreatic 
cancer.  In addition, the demonstration of feasibility of using EUS-FNA samples for 
marker analysis can provide the basis for similar studies using other markers such as 
KRAS mutation status, p53 immunolabeling and other markers that could be useful in 
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Table 1:  Baseline Patient Characteristics 
 
 All  
N=72 (%) 





Age (mean + SD) in 
years 
63.9 + 11.0 63.2 + 11.5 64.9 + 10.4 0.497 




























     
 
Table 2:  Baseline Tumor Characteristics 
 
 All  
N=72 (%) 





Size of tumor 
(mean + SD) in 
cm 
3.62 + 1.35  
 
3.52 + 1.17 
 































     
 
Table 3:  Clinical Outcomes 
 
 All  
N=72 (%) 























     
Table 4:  Pattern of Failure – Univariate and Multivariate Analyses 
 
 Unadjusted OR  
(95% Confidence 
Interval) 





Age>65 0.47 (0.18-1.22) 0.121 0.51 (0.17-1.54) 0.231 
Male gender 1.125 (0.43-2.92) 0.808 1.38 (0.42-4.49) 0.592 
Race 1.44 (0.73-2.82) 0.292 1.29 (0.62-2.69) 0.496 
Size of tumor  
>3 cm 
1.57 (0.54-4.60) 0.409 1.19 (0.32-4.47) 0.792 
Location of tumor  2.83 (1.02-7.85) 0.046 2.85 (0.98-2.69) 0.053 
Surgical resection  0.93 (0.33-2.61)  0.895 0.84 (0.26-2.77) 0.778 
DPC4 positive 
status 
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